Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Acute generalized exanthematous pustulosis induced by duloxetine
View through CrossRef
AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor. Some rare duloxetine‐induced hypersensitivity skin reactions have been reported. We report a case of acute generalized exanthematous pustulosis potentially induced by duloxetine. Skin pustules appeared 8 days after the introduction of duloxetine. Treatment with topical clobetasol propionate led to gradual remission of the lesions. As there are no cases of duloxetine‐induced acute generalized exanthematous pustulosis(AGEP) in the literature, we did a research in the World Health Organization (WHO) pharmacovigilance database (21 March 2022) and found three cases of duloxetine‐induced AGEP. The French causality assessment score for our case of duloxetine‐induced AGEP was 15 (C2S3). The Naranjo score was 7, indicating a possible correlation between AGEP and the use of duloxetine. This was consistent with the WHO causality score. We inform clinicians of the possibility of AGEP following therapy with duloxetine.
Title: Acute generalized exanthematous pustulosis induced by duloxetine
Description:
AbstractDuloxetine is a serotonin and norepinephrine reuptake inhibitor.
Some rare duloxetine‐induced hypersensitivity skin reactions have been reported.
We report a case of acute generalized exanthematous pustulosis potentially induced by duloxetine.
Skin pustules appeared 8 days after the introduction of duloxetine.
Treatment with topical clobetasol propionate led to gradual remission of the lesions.
As there are no cases of duloxetine‐induced acute generalized exanthematous pustulosis(AGEP) in the literature, we did a research in the World Health Organization (WHO) pharmacovigilance database (21 March 2022) and found three cases of duloxetine‐induced AGEP.
The French causality assessment score for our case of duloxetine‐induced AGEP was 15 (C2S3).
The Naranjo score was 7, indicating a possible correlation between AGEP and the use of duloxetine.
This was consistent with the WHO causality score.
We inform clinicians of the possibility of AGEP following therapy with duloxetine.
Related Results
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Dose–Concentration Relationship and Clinical Outcomes of Duloxetine in Generalized Anxiety Disorder
Background/Objectives: This study aimed to investigate plasma duloxetine concentrations, factors influencing these concentrations, and the relationship between plasma levels and cl...
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
COMPARISON OF DULOXETINE MONOTHERAPY VERSUS DULOXETINE AND GABAPENTIN COMBINATION THERAPY FOR NEUROPATHIC PAIN RELIEF
Background: Neuropathic pain is a complex and often refractory condition that significantly impairs quality of life. Pharmacological management remains the cornerstone of treatment...
Duloxetine for the Treatment of Major Depressive Disorder
Duloxetine for the Treatment of Major Depressive Disorder
Background. Existing therapies for depression frequently fail to provide full remission. This report evaluates the efficacy and safety of duloxetine, a dual reuptake inhibitor of s...
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Impact of Polymorphism of CYP2D6 on Equilibrium Concentration of Duloxetine in Patients Suffering from Major Depressive Disorder
Introduction
Duloxetine is commonly prescribed to patients with recurrent depressive disorder. Some part of patients in this group do not respond adequately to treatment regimen co...
Randomized active-controlled study of a single preoperative administration of duloxetine to treat postoperative pain and numbness after posterior lumbar interbody fusion surgery
Randomized active-controlled study of a single preoperative administration of duloxetine to treat postoperative pain and numbness after posterior lumbar interbody fusion surgery
Background:
This prospective, randomized, double-blinded, active controlled trial assessed whether a single preoperative administration of 40 mg of duloxetine could dec...
Cefoperazone-sulbactam-induced acute localized exanthematous pustulosis: A rare adverse drug reaction
Cefoperazone-sulbactam-induced acute localized exanthematous pustulosis: A rare adverse drug reaction
Acute localized exanthematous pustulosis (ALEP) is a rare, localized form of acute generalized exanthematous pustulosis, commonly induced by antibiotics. We present a 28-year-old f...
Rapid-Onset Hyponatremia Induced by Duloxetine in an Elderly Patient
Rapid-Onset Hyponatremia Induced by Duloxetine in an Elderly Patient
Duloxetine is a potent serotonin and noradrenaline re-uptake inhibitor that is used for the management of major depressive disorder and diabetic neuropathic pain. The common advers...
Duloxetine: An update
Duloxetine: An update
Duloxetine, a serotonin-norepinephrine reuptake inhibitor (SNRI), has established itself as a versatile therapeutic agent across a spectrum of psychiatric and neurological disorder...